Filing Details

Accession Number:
0001415889-24-022964
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-09-05 17:55:42
Reporting Period:
2024-09-03
Accepted Time:
2024-09-05 17:55:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1422142 Aadi Bioscience Inc. AADI Pharmaceutical Preparations (2834) 611547850
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1878692 Neil Desai C/O Aadi Bioscience, Inc.
17383 Sunset Boulevard, Suite A250
Pacific Palisades CA 90272
Executive Chairman No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-09-03 40,000 $1.71 1,171,543 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 639,698 Indirect See Footnote
Footnotes
  1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan originally adopted on September 20, 2021, as replaced on December 1, 2022, by the Reporting Person.
  2. Represents the weighted average share price of an aggregate total of 40,000 shares sold in the price range of $1.63 to $1.82 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. Shares held by Neil Prafulla Desai, Trustee of the Anishka Family Trust (the "Family Trust"). The Reporting Person is trustee of the Family Trust.
  4. Shares held by Anishka Irrevocable 2016 Trust dated October 19, 2016 (the "Irrevocable Trust"). The Reporting Person disclaims beneficial ownership of the shares held by the Irrevocable Trust except to the extent of any pecuniary interest therein, and this filing shall not be deemed an admission that Dr. Desai is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.